Ann: Cellmid's Evolis Registered in European Union (EU), page-2

ASX ANNOUNCEMENTCELLMID’S EVOLIS® REGISTERED IN EUROPEAN UNION (EU)• EU registration received for the évolis® product range: The évolis®Professional products can now be imported into all EU countries, including the UK, following receipt of comprehensive safety and compliance review against strict cosmetics regulations.• Distribution through large EU cosmetics retailer: The évolis® Professional product range (all 11 SKU’s) will be sold in EU member states by Cellmid’s cosmetics retailer partner. • Immediate sales through retail partner’s e-commerce: Sales through the e-commerce platform of Cellmid’s retail partner are expected to commence in 1HY20 in the EU, a large, discerning cosmetics market with relatively high disposable income, similar to the US. • Competitive market positioning with treatment claims: The évolis®Professional label will retain key treatment and efficacy claimsenabling competitive market positioning of the évolis® brand as natural, plant based and efficacious.SYDNEY, Tuesday, 30 April 2019: Cellmid Limited (ASX: CDY) is pleased to advise thatthe Company’s évolis® Professional anti-aging hair care products have been registered for sale in the European Union (EU). The registration represented the final step in a comprehensive regulatory compliance assessment of the évolis® Professional products before they could be freely sold in the UK and EU. Key treatment and efficacy claims have been retained on the product labels during the review process, which provides for strong market positioning as efficacious products that are derived from natural plant extracts.Cellmid has already established a partnership with one of the largest cosmetics retailers in Europe and it is expected that e-commerce sales on the partner’s platform will commence in 1H FY2020.According to industry reports, 50% of UK beauty consumers look for products made with natural ingredients and 25% of German consumers choose to buy natural products. In a discerning market such as the EU, the évolis® Professional products, based on plant extracts and with strong clinical evidence, are expected to be well positioned. Consistent with the Company’s strategic plan released to the market at the end February, the EU product registration represents yet another important milestone in the Company’s plans for the global expansion of the évolis® brand.